• Kobayashi M.Value-based Approach [45] Medical Devices, first to be subjected to the cost-effectiveness assessment. Introduction to analysis guideline (21) Considering how to deal with HTA for medical devices. Monthly Medical Information Express. 2021; 12:82-85 (in Japanese)

  • Kobayashi M.Value-based Approach [44] Analyze how to think about health outcomes and decision making. Introduction to analysis guideline(20)Discount-Important, but don’t go too deep!- Monthly Medical Information Express. 2021; 11:72-75 (in Japanese)

  • Kobayashi M.Value-based Approach [43] Varying the parameters enables to grasp the influence intuitively -Introduction to analysis guideline(19)Sensitivity analysis⑤Deterministic Sensitivity Analysis. Monthly Medical Information Express. 2021; 10:80-83 (in Japanese)

  • Kobayashi M.Value-based Approach -special volume- Understand the situation of the Japanese version of HTA evaluation. 25 products have been targeted since the start of enforcement. Is it cost-effective to use Kimria!? Monthly Medical Information Express. 2021; 9:70-75 (in Japanese)

  • Kobayashi M.Value-based Approach [42] Evaluate parameter uncertainty in a comprehensive manner -Introduction to analysis guideline(18) Sensitivity analysis④Probabilistic Sensitivity Analysis.  Monthly Medical Information Express. 2021; 8:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [41] Is model simulation a magic box? Considering validity and uncertainty  -Introduction to analysis guideline(17) Sensitivity analysis③Scenario analysis and sensitivity analysis. Monthly Medical Information Express. 2021; 7:80-81. (in Japanese)

  • Kobayashi M. Value-based Approach [40] Cost-effectiveness analysis is perishables! Pay attention to country of origin and expiration date.- Introduction to analysis guideline(16) Sensitivity analysis② Monthly Medical Information Express. 2021; 6:72-74. (in Japanese)

  • Kobayashi M. Value-based Approach [39] Learning from the cost effectiveness of Clopidogrel – Introduction to analysis guideline(15) Sensitivity analysis① How to interpret the model analysis.Monthly Medical Information Express. 2021; 5:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [38] Learning the SIR Model with Novel Coronavirus- Introduction to analysis guideline(14) Modeling⑨System dynamics. Monthly Medical Information Express. 2021; 3:72-74. (in Japanese)

  • Kobayashi M.Value-based Approach [37] Introduction to analysis guideline(13) Modeling⑧Limitations and countermeasures of Markov models. Monthly Medical Information Express. 2021; 2:78-80. (in Japanese)


Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis

and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA